SCHEMBL2004786

SCHEMBL2004786

CCN(CCN(CC)S(=O)(=O)c1ccc(OC)cc1)c1nc(Cc2ccccc2F)ns1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 4/20 0.41
CNR1 P21554 3/20 0.41
KEAP1 Q14145 1/20 0.41
LMNA P02545 4/20 0.37
HTT P42858 3/20 0.37
TP53 P04637 1/20 0.36
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TAS2R14 Q9NYV8 1/20 0.36
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
MMP1 P03956 1/20 0.35
MMP9 P14780 1/20 0.35
MMP13 P45452 1/20 0.35
ADAM17 P78536 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MMP3 P08254 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2008691 0.90 TAS2R14 (0.42) CNR2CNR1KEAP1LMNAHTT
SCHEMBL1020376 0.90 TAS2R14 (0.42) CNR2CNR1KEAP1LMNAHTT
SCHEMBL1020798 0.87 CNR2 (0.51) CNR2CNR1LMNAHTTALDH1A1
SCHEMBL1020990 0.86 CNR2 (0.46) CNR2CNR1LMNAHTTTAS2R14
SCHEMBL2007217 0.85 TAS2R14 (0.44) CNR2CNR1ALDH1A1TAS2R14
SCHEMBL1020236 0.84 CNR2 (0.42) CNR2CNR1LMNATP53ALDH1A1
SCHEMBL1018495 0.83 CNR2 (0.39) CNR2CNR1LMNATP53TAS2R14
SCHEMBL1021017 0.83 CNR2 (0.47) CNR2CNR1LMNATP53ALDH1A1
SCHEMBL1021520 0.82 CNR2 (0.48) CNR2CNR1TP53ALDH1A1TAS2R14
SCHEMBL1021265 0.82 NPC1 (0.35) LMNAALDH1A1KDM4ETSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US claimed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US claimed
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES SNCA, PARK7, PRNP CNR2 3443/4885CNR1 3094/4885KEAP1 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.